PTPA and acute lymphoblastic leukemia: These results offer a novel therapeutic approach where the combined targeting of T-ALL cells with a multi-kinase inhibitor and PP2A activator synergistically reduces growth by inhibiting multiple oncogenic pathways in both NOTCH-dependent and independent T-ALL cells (Figure 5).